Investor Presentation

Date: 26th October 2026 The Manager Listing Compliance Department National Stock Exchange of India Ltd. Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai-400051, India Symbol: SAKAR Sub: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Presentation on the Unaudited Financial Results. Please find attached the presentation on the Unaudited Financial Results (Consolidated and Standalone) for the quarter and half year ended September 30, 2026. This is submitted for your information and records. Thanking You, Yours faithfully, FOR, SAKAR HEALTHCARE LIMITED BHARAT SONI COMPANY SECRETARY AND COMPLIANCE OFFICER SAKAR HEALTHCARE LIMITED Investor Presentation | Q2 & H1FY27 Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Sakar Healthcare Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections. Financial & Operational Performance Q2 & H1FY27 Operational Highlights • 69 oncology product contracts executed; 45 commercial discussions currently underway; • Strengthened its global oncology presence in Q2 through portfolio expansion, wider market access across the EU, UK, Canada, Business momentum APAC and LATAM, and participation in CPHI Worldwide • 33 tech transfer projects underway with 4 Partners ; 33 site variations submitted & 11 approved (stringent market-EU & UK) across 18 cytotoxic molecules. Tech transfer • Accord has received 6 more product site variations approval by EMA (total now becomes 8 of 11 molecules) at our oncology site • 3 other site variation approval received from MHRA / EMA. (for 2-partners in the UK and 1 in Germany). • Shared 351 dossiers globally, of which 191 have been submitted and 22 have received Marketing Authorisations. • The approved MAs are well dispersed globally: Europe & UK-11, Latin America-6, APAC-4, Canada-1 Regulatory approvals • 36 EU MA applications, of which 16 are own filings; • 21 APIs developed in-house; 16 with Written Confirmation; 8 commercialised; 2 of 7 CEP applications approved, 5 currently under process Backward integration (API) • Commercial supplies to domestic & International Markets has started from the API-integrated, EU GMP-approved oncology FDF site • Cancer coverage widened to breast, lung, prostate, stomach, head & neck, colorectal, ovary, liver, kidney, thyroid, blood, bone- marrow and lymph General update • Sakar is moving towards an integrated, regulatory-driven business model, with greater value-chain integration improving supply-chain control, margin visibility and scalability. Q2 & H1FY27 – Consolidated Financial Highlights INR in Lakhs Revenue EBITDA PAT +52% +114% +149% 8,742 2,435 1,131 5,756 1,135 Q2FY26 Q2FY27 Q2FY26 Q2FY27 Q2FY26 Q2FY27 +45% +90% +134% 16,039 4,559 2,159 11,030 2,406 H1FY26 H1FY27 H1FY26 H1FY27 H1FY26 H1FY27 Q2 & H1FY27 – Consolidated Profit & Loss Statement Particulars (INR in Lakhs)​ Q2 FY27 Q2 FY26 Y-o-Y Q1 FY27 Q-o-Q H1FY27 H1FY26 Y-o-Y Revenue from Operations 8,741.61 5,756.04 52% 7,297.25 20% 16,038.86 11,029.66 45% COGS​ 4,573.56 3,040.64 3,458.22 8,031.78 5,935.88 Gross Profit 4,168.05 2,715.40 53% 3,839.03 9% 8,007.08 5,093.78 57% Gross Profit Margin (%) 48% 47% 53% 50% 46% Employee Expenses ​ 976.16 834.19 1,145.51 2,121.67 1,589.15 Other Expenses ​ 757.36 745.82 568.63 1,325.99 1,098.66 EBITDA 2,434.53 1,135.39 114% 2,124.89 15% 4,559.42 2,405.97 90% EBITDA Margin (%) 28% 20% 29% 28% 22% Other Income​ 28.13 121.46 154.39 182.52 160.85 Depreciation ​ 660.22 568.38 654.24 1,314.46 1,125.61 Finance Cost ​ 200.40 152.68 166.97 367.37 366.94 Profit before Tax 1,602.04 535.79 199% 1,458.07 10% 3,060.11 1,074.27 185% Profit before Tax(%) 18% 9% 20% 19% 10% Tax ​ 471.35 81.81 429.58 900.93 153.16 Profit After Tax 1,130.69 453.98 149% 1,028.49 10% 2,159.18 921.11 134% PAT Margin (%) 13% 8% 14% 13% 8% Basic EPS (As per Profit after Tax)​ 5.08 2.03 4.62 9.70 4.14 Q2 & H1FY27 – Consolidated Balance Sheet Particulars (INR in Lakhs) Sept 26 Mar 26 Particulars ( INR in Lakhs) Sept-26 Mar-26 ASSETS Equity Equity Share Capital 2,224.99 2,224.99 Non-Current Assets Other Equity 32,374.12 30,220.26 Property, Plant and Equipment 32,089.98 31,905.90 Total Equity 34,599.11 32,445.25 Capital work-in-progress 576.76 396.53 Liabilities Other Intangible Assets 1,268.32 742.70 Non-Current Liabilties Non Current Financial Assets 30.06 30.06 Financial Liabilities Other Non Current assets 1,548.78 979.90 (i) Borrowings 3,301.14 3,135.30 Total Non - Current Assets 35,513.90 34,055.09 Deferred Tax Liabilities (net) 1,392.57 1,285.82 Provisions, Non current Liablities 288.25 280.84 Current Assets Total Non-Current Liabilities 4,981.96 4,701.96 Inventories 9,720.52 7,004.14 Current Liabilities Current Financial Assets Financial liabilities (i) Borrowings 1,300.98 2,395.09 (i) Trade Receivables 3,940.87 5,008.33 (ii) Trade Payables 6,225.06 5,154.00 (ii) Cash and Cash Equivalents 4.78 4.21 (iii) Other Current Financial Liabilities 1,613.00 1,523.00 (iii) Bank balance 21.75 21.75 Other Current Liabilities 1,969.77 1,017.45 Current tax asset (net) 2,371.11 2,007.42 Current Tax Liabilities (Net) 883.05 864.19 Total Current Assets 16,059.03 14,045.85 Total Current Liabilities 11,991.86 10,953.73 Total Assets 51,572.93 48,100.94 Total Equity and Liabilities 51,572.93 48,100.94 Q2 & H1FY27 – Consolidated Cash Flow Statement Cash Flow Statement (INR in Lakhs) H1FY27 H1FY26 Profit before Tax 3,060.11 1,074.27 Operating Profit before Working Capital Changes 4,676.45 2,552.98 Changes in Working Capital -2,178.86 784.26 [Showing first 8,000 characters — download PDF for full document]